Open Label, Randomized, Parallel-Group, Multi-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of an AS03B /oil-in-water emulsion-adjuvanted (AS03B) split-virion vs. non-adjuvanted whole virion H1N1 influenza vaccine in UK children 6 months to 12 years of age

CS Waddington, WT Walker, C Oeser, A Reiner, T John, S Wilkins, M Casey, PE Eccleston, RJ Allen, I Okike, S Ladhani, E Sheasby, K Hoschler, N Andrews, P Waight, AC Collinson, PT Heath, A Finn, SN Faust, MD SnapeE Miller, Andrew Pollard

Research output: Contribution to journalArticle (Academic Journal)peer-review

Abstract

Open Label, Randomized, Parallel-Group, Multi-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of an AS03B /oil-in-water emulsion-adjuvanted (AS03B) split-virion vs. non-adjuvanted whole virion H1N1 influenza vaccine in UK children 6 months to 12 years of age
Translated title of the contributionOpen Label, Randomized, Parallel-Group, Multi-Centre Study to Evaluate the Safety, and Immunogenicity of an AS03B /oil-in-water emulsion-adjuvanted split-virion vs. non-adjuvanted whole virion H1N1 influenza vaccine in UK children 6 months to 12 years of age
Original languageEnglish
Article number1
Number of pages131
JournalHealth Technology Assessment
Volume14
Issue number46
DOIs
Publication statusPublished - Oct 2010

Fingerprint Dive into the research topics of 'Open Label, Randomized, Parallel-Group, Multi-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of an AS03B /oil-in-water emulsion-adjuvanted (AS03B) split-virion vs. non-adjuvanted whole virion H1N1 influenza vaccine in UK children 6 months to 12 years of age'. Together they form a unique fingerprint.

Cite this